Elsevier Health and OpenEvidence collaborated on the development of ClinicalKey AI with input from Cone Health, the University of New Mexico and more than 30,000 physicians.
Next week, on NACDS RxIMPACT Day on Capitol Hill, NACDS members and pharmacy advocates will push for PBM reform in-person to Congress and the Biden Administration.
Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.
Congress’ failure to enact PBM reforms for Americans in Medicare and Medicaid and for their pharmacies is nothing short of a wasted opportunity, pharmacy groups said.